Study of ISM3412 for Locally Advanced/Metastatic Solid Tumors
This study is testing a new oral medication called ISM3412 for people with locally advanced or metastatic (spread to other parts of the body) solid tumors. You might be able to join if your cancer has a specific genetic change called a homozygous MTAP deletion and has progressed after standard treatments, or if you can't tolerate standard treatments, or if there are no standard treatments available. The main goals are to see how safe ISM3412 is, what side effects it might cause, and to figure out the best dose to use in future studies. The study is currently recruiting participants.
- Study design
- This is an interventional study with an estimated enrollment of 114 participants. It has two parts: a dose escalation part and a dose selection optimization part.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track adverse events (side effects) for approximately 30 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
At a glance
Conditions
Where it's being run
10 sites across 9 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of dose-limiting toxicity (DLT) events31 days
To evaluate the safety and tolerability of ISM3412.
- Incidence and severity of adverse events (AEs)Approximately 30 months
To evaluate the safety and tolerability of ISM3412.
- Recommended phase 2 dose (RP2D)Approximately 30 months
To determine the RP2D of ISM3412.